Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | GCK | P35557 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2646184 | 1.00 | NPC1 (0.39) | NPC1RAB9AALDH1A1SMN1; SMN2GCK | |
| SCHEMBL2646712 | 0.84 | GCK (0.41) | GCKPIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL2646710 | 0.84 | GCK (0.41) | GCKPIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL2646581 | 0.84 | GCK (0.41) | GCKPIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL2646583 | 0.84 | GCK (0.41) | GCKPIK3CDPIK3CAPIK3CGPIK3CB | |
| SCHEMBL2646340 | 0.81 | GCK (0.57) | ALDH1A1SMN1; SMN2GCKMEN1KMT2A | |
| SCHEMBL2646193 | 0.81 | GCK (0.57) | ALDH1A1SMN1; SMN2GCKMEN1KMT2A | |
| SCHEMBL2646194 | 0.81 | GCK (0.57) | ALDH1A1SMN1; SMN2GCKMEN1KMT2A | |
| SCHEMBL2646344 | 0.81 | GCK (0.57) | ALDH1A1SMN1; SMN2GCKMEN1KMT2A | |
| SCHEMBL6257871 | 0.81 | GCK (0.41) | NPC1RAB9AALDH1A1GCKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242397-B1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | claimed |
| CN-1185219-C | Trans olefinic glucokinase activators | HOFFMANN LA ROCHE (CH) | 2005-01-19 | — | — | CN | claimed |
| CN-1411453-A | Trans olefinic glucokinase activators | HOFFMANN LA ROCHE (CH) | 2003-04-16 | — | — | CN | claimed |
| EP-1242397-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-25 | — | — | EP | claimed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | claimed |
| WO-2001044216-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-21 | — | — | WO | claimed |
| WO-2006043036-A2 | TREATMENT OF DIABETES | THE UNIVERSITY OF NEWCASTLE (GB) | 2006-04-27 | — | — | WO | disclosed |
| EP-1242397-B1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2005-09-28 | — | — | EP | disclosed |
| CN-1185219-C | Trans olefinic glucokinase activators | HOFFMANN LA ROCHE (CH) | 2005-01-19 | — | — | CN | disclosed |
| CN-1411453-A | Trans olefinic glucokinase activators | HOFFMANN LA ROCHE (CH) | 2003-04-16 | — | — | CN | disclosed |
| EP-1242397-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-25 | — | — | EP | disclosed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | disclosed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | disclosed |
| US-6353111-B1 | WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A | HOFFMANN-LA ROCHE INC. | 2002-03-05 | — | — | US | disclosed |
| WO-2001044216-A1 | TRANS OLEFINIC GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-06-21 | — | — | WO | disclosed |